Please use this identifier to cite or link to this item:
|Title:||Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation|
Dry powder inhaler
|Source:||Lee, S.H., Teo, J., Heng, D., Ng, W.K., Chan, H.-K., Tan, R.B.H. (2013-02). Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. European Journal of Pharmaceutics and Biopharmaceutics 83 (2) : 275-284. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejpb.2012.09.002|
|Abstract:||In combination antimicrobial therapy, the desired outcome is to broaden the antimicrobial spectrum and to achieve a possible synergistic effect. However, adverse antagonistic species may also emerge from such combinations, leading to treatment failure with serious consequences. It is therefore imperative to screen the drug candidates for compatibility and possible antagonistic interactions. The aim of this work was to develop a novel synergistic dry powder inhaler (DPI) formulation for antimicrobial combination therapy via the pulmonary route. Binary (ciprofloxacin hydrochloride and gatifloxacin hydrochloride, SD-CIP/GAT) and ternary (ciprofloxacin hydrochloride, gatifloxacin hydrochloride, and lysozyme, SD-CIP/GAT/LYS) combinations were prepared via spray-drying on a BUCHI® Nano Spray Dryer B-90. The powder morphologies were spherical with a slightly corrugated surface and all within the respirable size range. The powders yielded fine particle fractions (of the loaded dose) of over 40% when dispersed using an Aerolizer® at 60 L/min. Time-kill studies carried out against the respiratory tract infection-causing bacteria Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumonia, and Acinetobacter baumannii at 1 × the minimum inhibitory concentration (MIC) over 24 h revealed no antagonistic behavior for both the binary and ternary combinations. While the interactions were generally found to be indifferent, a favorable synergistic effect was detected in the dual combination (SD-CIP/GAT) when it was tested against P. aeruginosa bacteria. © 2012 Elsevier B.V. All rights reserved.|
|Source Title:||European Journal of Pharmaceutics and Biopharmaceutics|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 7, 2017
WEB OF SCIENCETM
checked on Nov 23, 2017
checked on Dec 11, 2017
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.